Surrozen, Inc./DE

Churchill Capital Corp VII (Nasdaq: CHFW), a blank-check company sponsored by Churchill Capital — the firm led by Michael Klein — filed an 8-K on June 7, 2024, in connection with its proposed business combination with Surrozen, Inc., a Delaware-incorporated clinical-stage biotechnology company focused on Wnt pathway therapeutics for organ and tissue repair. CHFW completed its IPO in 2021 targeting the healthcare and life sciences sector. The filing, carrying accession number 0000950170-24-070741, reflects activity in the de-SPAC process as the transaction advanced through required regulatory and disclosure milestones. Sign up at SpacDesk for full filing history, timeline data, and analytics on CHFW and hundreds of other SPAC transactions.